Zoetis Inc reports results for the quarter ended June 30 - Earnings Summary
Zoetis Inc reports results for the quarter ended June 30 - Earnings Summary
Zoetis Inc ZTS.N reported quarterly adjusted earnings of $1.87 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.76. The mean expectation of sixteen analysts for the quarter was for earnings of $1.86 per share. Wall Street expected results to range from $1.77 to $1.94 per share.
Revenue rose 0.3% to $2.47 billion from a year ago; analysts expected $2.50 billion.
Zoetis Inc's reported EPS for the quarter was $1.65.
The company reported quarterly net income of $691 million.
Zoetis Inc shares had risen by 3.5% this quarter and lost 40.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.9% in the last three months.
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Zoetis Inc is $99.00, about 24.9% above its last closing price of $74.39
This summary was machine generated from LSEG data August 6 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 1.86 | 1.87 | Beat |
Mar. 31 2026 | 1.61 | 1.53 | Missed |
Dec. 31 2025 | 1.40 | 1.48 | Beat |
Sep. 30 2025 | 1.62 | 1.70 | Beat |
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies